A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2

Background: Several biomarkers of treatment efficacy have been associated with a better prognosis in patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of biomarkers in the early treatment phase is unclear. Material and methods: In a complete national cohort of mRCC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Soerensen, Anne V., Geertsen, Poul F., Christensen, Ib J., Hermann, Gregers G., Jensen, Niels V., Fode, Kirsten, Petersen, Astrid, Sandin, Rickard, Donskov, Frede
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
ORIGINAL ARTICLE: Urologic cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819832/
https://www.ncbi.nlm.nih.gov/pubmed/26449266
http://dx.doi.org/10.3109/0284186X.2015.1091499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819832/
https://www.ncbi.nlm.nih.gov/pubmed/26449266
http://dx.doi.org/10.3109/0284186X.2015.1091499

Ejemplares similares